Cancer Clinical Trials

The following clinical trials are active at BIDMC and enrolling patients for experimental approaches to several different types of cancer.

• A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma - Learn More.


• A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) In Selected Advanced Solid Tumors - Learn More.


• A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  - Learn More.


• A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) - Learn More.


• Randomized, placebo-controlled, double blind phase II/III trial of oral isoquercetin to prevent venous thrombo-embolic events in cancer patients. - Learn More.


• A randomized, phase II study of weight-based versus standard dose enoxaparin thromboprophylaxis in high-risk hospitalized cancer patients.  - Learn More.


• Integration of Early Palliative Care in a Cancer Clinic - Learn More.


• A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  - Learn More.


• A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158) - Learn More.


• A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) In Selected Advanced Solid Tumors - Learn More.


• A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma - Learn More.

Updated November 2018.

Clinical trials are research studies that evaluate new procedures or drugs, weighing their effectiveness against current, standard protocols. BIDMC investigators studying cancer help "translate" their laboratory discoveries into clinical trials that eventually lead to improved treatments that benefit patients here and elsewhere.

Our specialty programs participate in a wide range of Phase I through Phase IV studies that investigate new uses of FDA approved drugs as well as novel investigational agents. Because the Cancer Center at BIDMC is an integral part of a full service hospital, patients enrolled in clinical trials receive cohesive, patient-focused, comprehensive care.

The Cancer Center's acclaimed clinical researchers offer patients novel treatment options through a number of clinical trials. Through these special research studies, patients can access new, potentially more effective treatment options before they become more widely available.

Our patients benefit from BIDMC's membership in the Dana-Farber/Harvard Cancer Center, the largest cancer research consortium in the country. This provides them with access to a broad array of the most current clinical trials.

BIDMC physician-scientists participate in clinical trials in connection with:

• Dana-Farber/Harvard Cancer Center (DF/HCC) 
• Eastern Cooperative Oncology Group (ECOG)
• National Cancer Institute (NCI)
• National Cancer Institute's Specialized Programs of Research Excellence (SPORE)
• Pancreatic Cancer Research Team (PCRT)